Gilead Sciences, Inc. is an American biopharmaceutical company headquartered in Foster City, California that focuses on researching and developing antiviral drugs used in the treatment of HIV/AIDS, hepatitis B, hepatitis C, influenza, and COVID-19, including ledipasvir/sofosbuvir and sofosbuvir.
Gilead Sciences, Inc. focuses on funding innovative and high-impact projects within their core therapeutic areas: HIV, liver disease (including HCV, HBV, and HDV), oncology (hematology and solid tumors), and inflammatory and respiratory diseases. The grant program emphasizes a strong commitment to delivering specific services that align with Gilead’s mission, particularly those that improve disease awareness, prevention, and care, especially among at-risk populations. Gilead supports diverse projects, from patient and community support initiatives such as educational events, resources, and testing/screening initiatives to medical and scientific support through continuing education programs for healthcare professionals, scientific conferences, and lecture series. The program aims at reducing disparities in care, enhancing disease awareness, and advancing the knowledge and skills of healthcare practitioners. Gilead Asia Grants specifically focus on HIV/AIDS and viral hepatitis with priorities on disease awareness and prevention, professional education, improving patient access and quality of care, increasing scientific capacity, and strengthening healthcare systems. There are no minimum or maximum funding request amounts, encouraging applicants to request funding based on programmatic needs.